A private briefing.
Hosted by our CEO.
A 45-minute confidential briefing with Peter Moeller, CEO of Moeller & Co. Capital — on Moroxite AB and the team replacing autologous bone harvest in a USD 10 billion spinal fusion market. FDA Breakthrough Device. Q1 2028 first-in-human.
14
Days
05
Hrs
47
Min
21
Sec
FDA
Breakthrough
$10B+
Global market
1.0M
Surgeries / yr
Q1 2028
First-in-human
Reserve your seat
Confidential briefing
Hosted by
Peter Moeller
CEO, Moeller & Co. Capital.
Founder and CEO of Moeller & Co. Capital — the Swiss boutique sourcing Moroxite AB for a select group of family offices and professional investors. Peter leads the briefing personally and answers questions live.
Hosted by
Moeller & Co. Capital · Zurich
Agenda · 45 minutes
- 00:00Why now — the orthobiology shift in spinal fusion
- 08:00The Moroxite platform · preclinical evidence
- 20:00FDA Breakthrough pathway and clinical roadmap
- 30:00Capital structure, terms, and exit landscape
- 38:00Live Q&A — partner and CEO
The buyers are already named.
CG Bio Novosis · acquired for USD 500M, early-stage.
Medtronic
Stryker
Zimmer Biomet
Globus Medical
J&J DePuy
NuVasive
Who attends?+
Family offices, HNW individuals, institutional allocators, and strategic corporates. Each registration is reviewed; we may decline submissions outside the firm's investor mandate.
Will materials be shared?+
Registered attendees receive a 12-page pre-read memo 48 hours before the session. The full data room opens after a brief qualification call.
Is this a solicitation?+
No. The webinar is informational and restricted to professional investors under Swiss FinSA. No commitment is requested or accepted on the call.
What if I cannot attend live?+
A confidential recording is sent to registered attendees within 24 hours. Q&A questions can be submitted in advance through the registration form.
Ready to reserve? Seats close 24 hours before the briefing.
Reserve seat →